All News

smartwatch wearable

Activity Trackers Can Predict RA Flares

MedPage Today

People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated.

Read Article
lung image

Lung Involvement in Pre-RA

Kristen Demoruelle, MD

When I see patients with RA-associated ILD, I’m often asked: “Are the lungs and joints really connected?” The answer is yes, and the connection extends further back than some may realize. While RA is defined by inflammation of the joints, extra-articular complications of the lung are well recognized. ILD has often been viewed as a complication of longstanding RA, but it can also appear before joint disease in a subset of patients.

Read Article
RheumNow Podcast square

How Does Your Garden Grow (9.26.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 

Read Article
pills.bottle.hand__0.jpg

Polypharmacy Impairs Rheumatoid Arthritis Outcomes

Jack Cush, MD

A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs). 

Read Article
T%20cell.jpg

Rheumatoid arthritis begins long before symptoms

EurekAlert!

Scientists have discovered that rheumatoid arthritis (RA) doesn’t start when the pain begins. It silently starts years earlier.The new research reveals that people at risk for RA experience dramatic immune system changes long before they feel symptoms.   

Read Article
IPF.CT_.jpg

High-Resolution CT in CTD-Interstitial Lung Disease

Jack Cush, MD

A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).

Read Article
Lung Involvement in Pre-RA When I see patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), I’m often asked: “Are the lungs and joints really connected?” The answer is yes, and the connection extends further back than some may realize. https://t.co/7Yl0flhJ3p
Dr. John Cush RheumNow ( View Tweet)
Detection, Monitoring & Management of Autoimmune ILD The American Journal of Managed Care has reviewed the approach to patients with ILD; a significant cause of morbidity and mortality in those with SARDs, including RA, SSc, and IIM. https://t.co/xtRfLNyZA6 https://t.co/S9JFlMd9CN

Links:

Dr. John Cush RheumNow ( View Tweet)
RA at risk for pneumonia & hospitalisation. Pop/ study (41187 RA vs 205935 matched controls). w/ 4yrs F/U, RA had signif. more pneumonia (adj HR 1.73) & hospitaliz (aHR 2.26); higher w/ seropositives (aHR 1.86 & 2.52) & bDMARDs (1.73), but not tsDMARDs (0.93) https://t.co/XJE1FqVqCn
Dr. John Cush RheumNow ( View Tweet)
Polypharmacy Impairs Rheumatoid Arthritis Outcomes A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significantly lower treatment responses and more serious adverse events (SAEs). https://t.co/QAJYzHEaFv https://t.co/vUeBsLCYNE

Links:

Dr. John Cush RheumNow ( View Tweet)
TREG EULAR 2025 Review of Rheumatoid Arthritis & Vasculitis abstracts https://t.co/3GdLOYssjU via @YouTube

Links:

Dr. John Cush RheumNow ( View Tweet)

Data from 2019 National Health Survey on 87,678 ppl -- 21.6% had chronic back pain. Chronic LBP assoc w/ multimorbidity in 62% (esp. CV dz, arthritis, & depression) https://t.co/LFdWr0s6tg https://t.co/Enj162VYJl

Links:

Dr. John Cush RheumNow ( View Tweet)
Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies. https://t.co/Culzv9bSD4
Dr. John Cush RheumNow ( View Tweet)
Screening for RA-ILD: metanalysis of 9 studies, 1380 RA pts - RA-ILD prevalence ranged from 6.7-42.7%; 18.9% via HRCT. None examined risk factors. Male sex & smoking were ~12% higher in RA-ILD & RA disease onset age was 7 years higher in RA-ILD pts. DAS didnt https://t.co/qA2oitwQg5
Dr. John Cush RheumNow ( View Tweet)
Prospective French study of 101 RA-ILD (mean 66yrs) assessed for shorter WBC telomere length (LTL); short LTL seen in 43% & assoc w/ lower FVC (82% vs 93%pred) & TLCO (49% vs 63%) & greater FVC/DLCO decline & lung progression after 12 mos (47% vs 22%; p<0.001) https://t.co/ObVeon0riy
Dr. John Cush RheumNow ( View Tweet)
Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in ED or hospitalization. But NSIA led to missed work (37%) or RA Rx interruptions (26%) and more fatigue. NSIE may contribute to more disease flares https://t.co/Al5B5oxvFg
Dr. John Cush RheumNow ( View Tweet)
Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4

Links:

Dr. John Cush RheumNow ( View Tweet)
GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated. https://t.co/x2soZxuZCO https://t.co/84lnQOzsvP

Links:

Dr. John Cush RheumNow ( View Tweet)
Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
Dr. John Cush RheumNow ( View Tweet)
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×